Glonghui May 27 δΈ¨ Minotis (603538)(603538allmegawaysgames.SH) Announcementallmegawaysgames, recentlyallmegawaysgamesThe company's holding subsidiary Zhejiang Minovanovic Propifenolate Fumarate and Tenofovir API passed the technical review of the Center for Drug Evaluation of the State Food and Drug Administration (hereinafter referred to as "CDE"), and registered in the CDE API, pharmaceutical excipients and pharmaceutical packaging materials. The registration information disclosure platform displays that the registration number has changed to "A" status.
The name of the drug substance is tenofovir propionate and is suitable for the treatment of chronic hepatitis B in adults and adolescents (age 12 years and above, weighing at least 35kg).
Zhejiang Minovantis's Tenofovir Propifenumarate API has passed the CDE technical review, which proves that the API has met relevant national technical standards for drug review and can be sold to the domestic market, which will further enrich the subsidiary's product line and help Expand the company's business areas, help further expand the company's integrated production scope of API preparations, and enhance the company's integrated production advantages.
